{
    "organizations": [],
    "uuid": "93286f866651262372cd4030610a4d03bb8ea47d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-arca-biopharma-anticipates-meeting/brief-arca-biopharma-anticipates-meeting-with-fda-in-q2-idUSASB0C7ED",
    "ord_in_thread": 0,
    "title": "BRIEF-ARCA Biopharma Anticipates Meeting With FDA In Q2",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 32 PM / Updated 7 minutes ago BRIEF-ARCA Biopharma Anticipates Meeting With FDA In Q2 Reuters Staff Feb 26 (Reuters) - ARCA Biopharma Inc: * ARCA BIOPHARMA REPORTS TOPLINE PHASE 2B RESULTS FOR GENETIC-AF CLINICAL TRIAL * ARCA BIOPHARMA INC - ‍ANTICIPATES MEETING WITH U.S. FDA IN Q2 OF 2018 TO REVIEW PHASE 2 DATA AND PHASE 3 DEVELOPMENT PLAN​ * ARCA BIOPHARMA INC - ‍GENCARO DEMONSTRATES COMPARABLE EFFICACY TO ACTIVE CONTROL AND TREND FOR POTENTIAL GENCARO SUPERIORITY IN US PATIENT COHORT​ * ARCA BIOPHARMA INC - ‍SAFETY DATA INDICATED THAT GENCARO WAS GENERALLY SAFE AND WELL-TOLERATED IN AF/HEART FAILURE POPULATION​ * ARCA BIOPHARMA INC - ‍THREE PATIENTS DIED IN LONG-TERM TREATMENT EXTENSION PERIOD AFTER RECEIVING GENCARO FOR MORE THAN A YEAR​ * ARCA BIOPHARMA INC - ‍ENDED 2017 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $11.8 MILLION​ * ARCA BIOPHARMA - ‍BELIEVES FUNDS, WITH NET PROCEEDS OF ABOUT $3.4 MILLION RAISED IN JAN WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2018​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-26T15:29:00.000+02:00",
    "crawled": "2018-02-26T15:50:56.053+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "biopharma",
        "anticipates",
        "meeting",
        "fda",
        "q2",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "arca",
        "biopharma",
        "inc",
        "arca",
        "biopharma",
        "report",
        "topline",
        "phase",
        "2b",
        "result",
        "clinical",
        "trial",
        "arca",
        "biopharma",
        "inc",
        "meeting",
        "fda",
        "q2",
        "review",
        "phase",
        "data",
        "phase",
        "development",
        "arca",
        "biopharma",
        "inc",
        "demonstrates",
        "comparable",
        "efficacy",
        "active",
        "control",
        "trend",
        "potential",
        "gencaro",
        "superiority",
        "u",
        "patient",
        "arca",
        "biopharma",
        "inc",
        "data",
        "indicated",
        "gencaro",
        "generally",
        "safe",
        "failure",
        "arca",
        "biopharma",
        "inc",
        "patient",
        "died",
        "treatment",
        "extension",
        "period",
        "receiving",
        "gencaro",
        "arca",
        "biopharma",
        "inc",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "totaling",
        "arca",
        "biopharma",
        "fund",
        "net",
        "proceeds",
        "million",
        "raised",
        "jan",
        "sufficient",
        "fund",
        "operation",
        "end",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}